# APOC1

## Overview
The APOC1 gene encodes apolipoprotein C1, a small protein that plays a crucial role in lipid metabolism. Apolipoprotein C1 is primarily involved in modulating the interactions of lipoproteins with various receptors and enzymes, influencing processes such as the hepatic uptake of lipoprotein remnants and the activity of cholesteryl ester transfer protein (CETP) (Jong1999Role; Rouland2022Role). Structurally, the protein is characterized by amphipathic alpha helices that facilitate its interaction with lipoproteins, contributing to its function in lipid transport and metabolism (Rozek1995Conformation). Beyond its metabolic roles, APOC1 is implicated in immune responses and has been associated with various diseases, including metabolic syndrome, cancer, and cardiovascular conditions, highlighting its potential as a biomarker and therapeutic target (Cao2023APOC1; Wang2019Diagnostic).

## Structure
Apolipoprotein C1 (APOC1) is a 57 amino acid polypeptide with a molecular weight of approximately 6.6 kDa (Jong1999Role; Rouland2022Role). The primary structure of APOC1 is characterized by a high lysine content and the absence of histidine, tyrosine, and cysteine residues (Jong1999Role; Shulman1975Thf). 

In terms of secondary structure, APOC1 forms amphipathic alpha helices. Studies using nuclear magnetic resonance (NMR) have shown that in the presence of sodium dodecyl sulfate (SDS), fragments of APOC1, specifically residues 7-24 and 35-53, adopt helical conformations (BolanosGarcia2003On; Rozek1995Conformation). These helices are stabilized by hydrophobic interactions and exhibit an amphipathic character, with distinct hydrophobic and hydrophilic faces (Rozek1995Conformation).

The tertiary structure of APOC1 involves a slightly bent alpha helix that can form dimers through hydrophobic interactions (McPherson2019The). The quaternary structure is characterized by the ability of APOC1 to form dimers, which can interact with other monomers to create continuous bands or sheets in certain crystal forms (McPherson2019The). These structural features contribute to APOC1's role in lipid metabolism and its interaction with lipoproteins.

## Function
Apolipoprotein C1 (APOC1) is a small protein primarily involved in lipoprotein metabolism. It plays a significant role in modulating the interaction of lipoproteins with various receptors and enzymes. APOC1 is known to inhibit the binding of very low-density lipoproteins (VLDL) to their receptors, such as the low-density lipoprotein receptor (LDLR) and LDL receptor-related protein (LRP), by altering the conformation of apolipoprotein E (apoE) rather than displacing it (Jong1999Role; Weisgraber1990Apolipoprotein). This inhibition affects the hepatic uptake of VLDL remnants, contributing to elevated plasma triglyceride levels (Jong1996In).

APOC1 also inhibits the activity of cholesteryl ester transfer protein (CETP), which is involved in the exchange of cholesterol esters and triglycerides between high-density lipoproteins (HDL) and triglyceride-rich lipoproteins (TRLs). This inhibition is particularly effective when APOC1 is associated with HDL, leading to increased HDL-cholesterol levels (Rouland2022Role). Additionally, APOC1 can activate lecithin-cholesterol acyltransferase (LCAT), although to a lesser extent than apolipoprotein A1 (apoA1), influencing cholesterol esterification (Jong1999Role). These functions highlight APOC1's complex role in lipid metabolism and its potential impact on cardiovascular health.

## Clinical Significance
Alterations in the expression of the APOC1 gene have been implicated in several diseases, particularly in the context of lipid metabolism and cancer. In hepatitis B virus-related hepatocellular carcinoma (HCC), APOC1 expression is significantly altered, with studies indicating its potential as a biomarker for diagnosis and prognosis. Differential expression of APOC1 in tumor versus non-tumor tissues has been observed, and its association with overall survival suggests clinical relevance in HCC prognosis (Wang2019Diagnostic).

In metabolic syndrome, APOC1 has been identified as a novel locus associated with elevated plasma glucose and central obesity. Its role in atherogenic dyslipidemia and vascular inflammation further underscores its significance in metabolic disorders. The gene's complex region, which includes APOE and pseudo-APOC genes, complicates its study, but evidence suggests that APOC1 may be a target for early intervention in metabolic syndrome (Avery2011A).

APOC1 is also involved in the metastasis of clear cell renal cell carcinoma (ccRCC), where its overexpression activates the STAT3 pathway, promoting metastatic potential. This highlights its role in cancer progression and potential as a therapeutic target (Li2020ApoC1). Additionally, hypomethylation of APOC1 has been linked to an increased risk of coronary artery disease, suggesting that epigenetic changes in this gene may contribute to cardiovascular conditions (Li2022Association).

## Interactions
Apolipoprotein C1 (APOC1) is involved in various interactions with proteins that play significant roles in lipid metabolism. APOC1 is known to associate with triglyceride-rich lipoproteins and high-density lipoproteins (HDL), exchanging between lipoprotein classes through amphipathic helix motifs (Fuior2019Apolipoprotein). It interacts with several apolipoproteins, including apoA1, B, C2, and C3, and enzymes such as hepatic lipase (LIPC), cholesteryl ester transfer protein (CETP), lecithin cholesterol acyltransferase (LCAT), and paraoxonase (PON1) (Fuior2019Apolipoprotein).

APOC1 inhibits the binding of lipoproteins to receptors mediated by apolipoprotein E (apoE), particularly affecting the low-density lipoprotein receptor-related protein (LRP) and low-density lipoprotein receptor (LDLR) (Weisgraber1990Apolipoprotein; Fuior2019Apolipoprotein). It displaces apoE from beta-migrating very low-density lipoproteins (beta-VLDL), reducing their binding activity to LRP (Weisgraber1990Apolipoprotein). APOC1 also inhibits the activity of lipoprotein lipase (LPL) and hepatic lipase, contributing to increased very low-density lipoprotein (VLDL) levels and hyperlipidemia (Fuior2019Apolipoprotein).

In addition to its role in lipid metabolism, APOC1 is involved in immune-related processes, interacting with proteins such as APOE, SAA1, APOF, LPL, and APOC2, which are associated with immune infiltration and inflammatory responses in the tumor microenvironment (Cao2023APOC1).


## References


[1. (Li2022Association) Wei Li, Yongyi Wang, Ritai Huang, Feng Lian, Genxing Xu, Weijun Wang, and Song Xue. Association of lipid metabolism-related gene promoter methylation with risk of coronary artery disease. Molecular Biology Reports, 49(10):9373–9378, August 2022. URL: http://dx.doi.org/10.1007/s11033-022-07789-0, doi:10.1007/s11033-022-07789-0. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11033-022-07789-0)

[2. (Cao2023APOC1) Xiying Cao, Bingqun Wu, Shaoming Guo, Weixiang Zhong, Shenyu Zhu, Zuxiong Zhang, Liang Gu, and Hui Li. Apoc1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis. Pathology and Oncology Research, March 2023. URL: http://dx.doi.org/10.3389/pore.2023.1610976, doi:10.3389/pore.2023.1610976. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/pore.2023.1610976)

[3. (Rozek1995Conformation) Annett Rozek, Garry W. Buchko, and Robert J. Cushley. Conformation of two peptides corresponding to human apolipoprotein c-i residues 7-24 and 35-53 in the presence of sodium dodecyl sulfate by cd and nmr spectroscopy. Biochemistry, 34(22):7401–7408, June 1995. URL: http://dx.doi.org/10.1021/bi00022a013, doi:10.1021/bi00022a013. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi00022a013)

[4. (Jong1996In) M C Jong, V E Dahlmans, P J van Gorp, K W van Dijk, M L Breuer, M H Hofker, and L M Havekes. In the absence of the low density lipoprotein receptor, human apolipoprotein c1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. Journal of Clinical Investigation, 98(10):2259–2267, November 1996. URL: http://dx.doi.org/10.1172/jci119036, doi:10.1172/jci119036. This article has 92 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci119036)

[5. (Rouland2022Role) Alexia Rouland, David Masson, Laurent Lagrost, Bruno Vergès, Thomas Gautier, and Benjamin Bouillet. Role of apolipoprotein c1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review. Cardiovascular Diabetology, December 2022. URL: http://dx.doi.org/10.1186/s12933-022-01703-5, doi:10.1186/s12933-022-01703-5. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12933-022-01703-5)

[6. (Weisgraber1990Apolipoprotein) K H Weisgraber, R W Mahley, R C Kowal, J Herz, J L Goldstein, and M S Brown. Apolipoprotein c-i modulates the interaction of apolipoprotein e with beta-migrating very low density lipoproteins (beta-vldl) and inhibits binding of beta-vldl to low density lipoprotein receptor-related protein. Journal of Biological Chemistry, 265(36):22453–22459, December 1990. URL: http://dx.doi.org/10.1016/s0021-9258(18)45726-2, doi:10.1016/s0021-9258(18)45726-2. This article has 176 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)45726-2)

[7. (Wang2019Diagnostic) Xiangkun Wang, Yizhen Gong, Teng Deng, Linbo Zhang, Xiwen Liao, Chuangye Han, Chengkun Yang, Jianlu Huang, Qiaoqi Wang, Xiaowei Song, Tengfang Zhang, Tingdong Yu, Guangzhi Zhu, Xinping Ye, and Tao Peng. Diagnostic and prognostic significance of mrna expressions of apolipoprotein a and c family genes in hepatitis b virus‐related hepatocellular carcinoma. Journal of Cellular Biochemistry, 120(10):18246–18265, June 2019. URL: http://dx.doi.org/10.1002/jcb.29131, doi:10.1002/jcb.29131. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.29131)

[8. (Avery2011A) Christy L. Avery, Qianchuan He, Kari E. North, Jose L. Ambite, Eric Boerwinkle, Myriam Fornage, Lucia A. Hindorff, Charles Kooperberg, James B. Meigs, James S. Pankow, Sarah A. Pendergrass, Bruce M. Psaty, Marylyn D. Ritchie, Jerome I. Rotter, Kent D. Taylor, Lynne R. Wilkens, Gerardo Heiss, and Dan Yu Lin. A phenomics-based strategy identifies loci on apoc1, brap, and plcg1 associated with metabolic syndrome phenotype domains. PLoS Genetics, 7(10):e1002322, October 2011. URL: http://dx.doi.org/10.1371/journal.pgen.1002322, doi:10.1371/journal.pgen.1002322. This article has 85 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1002322)

[9. (Shulman1975Thf) R S Shulman, P N Herbert, K Wehrly, and D S Fredrickson. Thf complete amino acid sequence of c-i (apolp-ser), an apolipoprotein from human very low density lipoproteins. Journal of Biological Chemistry, 250(1):182–190, January 1975. URL: http://dx.doi.org/10.1016/s0021-9258(19)41998-4, doi:10.1016/s0021-9258(19)41998-4. This article has 99 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(19)41998-4)

[10. (Jong1999Role) Miek C. Jong, Marten H. Hofker, and Louis M. Havekes. Role of apocs in lipoprotein metabolism: functional differences between apoc1, apoc2, and apoc3. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(3):472–484, March 1999. URL: http://dx.doi.org/10.1161/01.atv.19.3.472, doi:10.1161/01.atv.19.3.472. This article has 421 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1161/01.atv.19.3.472)

[11. (BolanosGarcia2003On) Victor Martin Bolanos-Garcia and Ricardo Nunez Miguel. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Progress in Biophysics and Molecular Biology, 83(1):47–68, September 2003. URL: http://dx.doi.org/10.1016/s0079-6107(03)00028-2, doi:10.1016/s0079-6107(03)00028-2. This article has 66 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0079-6107(03)00028-2)

[12. (McPherson2019The) Alexander McPherson and Steven B. Larson. The structure of human apolipoprotein c-1 in four different crystal forms. Journal of Lipid Research, 60(2):400–411, February 2019. URL: http://dx.doi.org/10.1194/jlr.m089441, doi:10.1194/jlr.m089441. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1194/jlr.m089441)

[13. (Li2020ApoC1) Yang-ling Li, Lin-wen Wu, Ling-hui Zeng, Zuo-yan Zhang, Wei Wang, Chong Zhang, and Neng-ming Lin. Apoc1 promotes the metastasis of clear cell renal cell carcinoma via activation of stat3. Oncogene, 39(39):6203–6217, August 2020. URL: http://dx.doi.org/10.1038/s41388-020-01428-3, doi:10.1038/s41388-020-01428-3. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-020-01428-3)

[14. (Fuior2019Apolipoprotein) Elena V. Fuior and Anca V. Gafencu. Apolipoprotein c1: its pleiotropic effects in lipid metabolism and beyond. International Journal of Molecular Sciences, 20(23):5939, November 2019. URL: http://dx.doi.org/10.3390/ijms20235939, doi:10.3390/ijms20235939. This article has 116 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20235939)